Finance entity
markets is the sole category represented across all 1 tracked stories. bioAffinity Technologies, Inc. is most often covered alongside CyPath Lung, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 5.9 for that window.
Last mentioned: 6d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. bioAffinity Technologies, Inc. is most often covered alongside CyPath Lung, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 5.9 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.2 for the same window. bioAffinity Technologies, Inc. appears in 1 tracked Finance story from September 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 34 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering bioAffinity Technologies, Inc.. Shared-story counts are live from our verified record — not editorial picks.
A 1-for-15 reverse split and a surveillance announcement produced a 47.95% one-day jump for thinly traded bioAffinity Technologies. But only $2.4 million in cash and a warrant overhang complicate the move's sustainability.
bioAffinity Technologies, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
